"Best time to take retatrutide" is rising faster than any other timing search in this cluster, and the honest answer applies to all three weekly molecules: no label or trial names a best time of day. What the labels do set are three other kinds of timing rule — how late a missed dose can be given, how far apart two doses must be when the weekly day moves, and, for one product only, a rule about the morning. This page sets those rules side by side for semaglutide, tirzepatide and retatrutide, from the labels read on 2026-10-02 and the trial records, with the half-life arithmetic that explains them. It reports; it sets no schedule.
The dose ladders are on the chart of GLP-1 doses by product; where the injection goes is on where to inject tirzepatide, where to inject semaglutide and how retatrutide is injected in the trials.
The rules, product by product
| Rule | Ozempic (injection) | Wegovy (injection) | Mounjaro / Zepbound | Retatrutide |
|---|---|---|---|---|
| Frequency | Once weekly, same day | Once weekly, same day | Once weekly | Once weekly in every trial read |
| Time of day | Any, with or without meals | Any, with or without meals | Any, with or without meals | No label |
| Missed dose | Within 5 days | Only if next dose is more than 2 days away | Within 4 days (96 h) | No label |
| Several missed doses | Not addressed in the text read | 2 or more in a row: escalation restarts lower | Not addressed in the text read | No label |
| Moving the weekly day | At least 2 days (48 h) apart | Not stated in the text read | At least 3 days (72 h) apart | No label |
| Half-life on record | About 1 week | About 1 week | About 5 days (5–6 days in obesity) | About 6 days (phase 1b) |
| Peak after a dose | 1 to 3 days | 1 to 3 days | Median 24 h (8–72 h) | Not on a label |
Two things stand out. The time-of-day row is uniform: every injectable label uses the same phrase, "at any time of day, with or without meals". And the rules that do vary — four days, five days, "more than 2 days away" — line up with the half-lives: the shorter-acting tirzepatide has the shorter missed-dose window and the longer minimum gap between doses when the day changes. The June 2026 Wegovy restart wording and what a missed week does to drug levels are covered on the GLP-1 missed-dose page.
Why the time of day does not move the numbers
A weekly molecule decays slowly enough that a few hours barely registers. On the labels' half-lives, the fraction of one dose still circulating (arithmetic by this site):
| Time after the dose | Semaglutide (t½ about 7 days) | Tirzepatide (t½ about 5 days) | Retatrutide (t½ about 6 days) |
|---|---|---|---|
| 2 days | 82% | 76% | 79% |
| 4 days | 67% | 57% | 63% |
| 5 days | 61% | 50% | 56% |
| 7 days | 50% | 38% | 45% |
Shifting an injection by 12 hours moves the 7-day figure by about 2.5 percentage points for semaglutide and about 3 for tirzepatide. Over repeated weekly doses the levels settle at a steady state — after 4 weeks for tirzepatide and 4 to 5 weeks for semaglutide, per the labels — and a consistent day keeps that steady; the hour within the day is a much smaller effect. The detail for each molecule is on the semaglutide, tirzepatide and retatrutide half-life pages, and the general relation between half-life and schedule on peptide dosing frequency.
The one product that does have a time of day
The semaglutide tablet is the exception, and the reason is absorption, not effect. The RYBELSUS and OZEMPIC tablets label (effective 2026-01-30) and the Wegovy tablet section of the Wegovy label give the tablet once daily, on an empty stomach in the morning, with no more than 4 ounces of plain water, and then a wait of at least 30 minutes before food, drink or other oral medicines; a missed tablet is skipped and the next taken the following day. Oral semaglutide is only about 1% to 2% absorbed, per the Wegovy label, and Novo Nordisk's own dosing-schedule trial (van Hout et al., Clinical Pharmacokinetics 2023, 156 healthy volunteers) found that pre-dose fasts shorter than overnight gave significantly lower exposure. That rule belongs to the tablet. It has been carried over in some places to the weekly injection, which no label supports. The tablet's strengths against the injection are on the semaglutide dosage page.
Retatrutide: no label, so no rule
Every retatrutide phase 2 and phase 3 arm read on ClinicalTrials.gov gives the drug once weekly by subcutaneous injection, and none of the registry entries records a time of day. The half-life of about 6 days comes from one phase 1b trial (NCT04143802; Urva et al., Lancet 2022). On that figure it sits between semaglutide and tirzepatide, which is why weekly dosing works — but a missed-dose window and a day-change rule are things a label sets, and borrowing tirzepatide's four days or Ozempic's five for retatrutide would be a guess dressed as a rule. Its trial doses in syringe units are on the retatrutide dosage page.
What the evidence on timing does not show
No trial found compares morning with evening injection of a weekly GLP-1. A 2026 systematic review asking whether any day of the week is better for semaglutide or tirzepatide (La Vignera and Condorelli, Medicina 2026) screened 1,000 records, kept three, and found "no studies directly compared different days of the week" for the injections; it concluded that current evidence does not support an optimal day. Side-effect timing — nausea peaking in the days after a dose — is sometimes given as a reason to choose a day; that is a practical preference, not a label rule, and no trial reviewed tests it. Nothing on this page is an instruction; timing and dose belong with the prescriber.
Sources and dates
Opened 2026-10-02: the OZEMPIC injection label via openFDA (effective 2026-07-30), sections 2.1 and 12.3; the WEGOVY injection and tablet label via DailyMed (set id ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18), sections 2 and 12.3; the MOUNJARO label via openFDA (effective 2026-07-29) and the ZEPBOUND label via openFDA (effective 2026-08-28), sections 2 and 12.3; the RYBELSUS and OZEMPIC tablets label via openFDA (effective 2026-01-30), section 2.1; ClinicalTrials.gov records for retatrutide (33, searched 2026-10-02); a PubMed search for GLP-1 or semaglutide or tirzepatide with time of day, morning, evening or bedtime administration (16 records, none comparing times of day for a weekly injection); PubMed abstracts of La Vignera and Condorelli, Medicina 2026 (PMID 42654433) and van Hout et al., Clin Pharmacokinet 2023 (PMID 36932262). The retatrutide half-life is as cited on this site's retatrutide half-life page. Percentages are arithmetic by this site. Corrections go to the contact page.